NCT03179878View on ClinicalTrials.gov

Safety and Tolerability of SYNB1020-CP-001

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 16, 2017

Primary Completion Date

November 2, 2017

Study Completion Date

April 11, 2018

Conditions
Healthy VolunteerUrea Cycle Disorder
Interventions
DRUG

Placebo

Placebo

DRUG

SYNB1020

Investigational Product

Trial Locations (1)

21225

Parexel, Brooklyn

Sponsors

Lead Sponsor

Synlogic
All Listed Sponsors
lead

Synlogic

INDUSTRY

NCT03179878 - Safety and Tolerability of SYNB1020-CP-001 | Biotech Hunter | Biotech Hunter